# Jianghua Ding

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jianghua-ding/

## Facts

| Field | Value |
| --- | --- |
| Citations | 284 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 10 |
| i10-index | 10 |
| Last Known Institution | Jiujiang University |
| OpenAlex ID | https://openalex.org/A5086624484 |
| ORCID iD | 0000-0003-4476-4398 |
| Works | 34 |

## Researcher papers

- [Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl‐2 and Bax and suppression of <scp>VEGF</scp>](https://scholariq.org/papers/aspirin-inhibits-proliferation-and-induces-apoptosis-of-multiple-myeloma-cells/)
- [JPEG Encryption with File Size Preservation](https://scholariq.org/papers/jpeg-encryption-with-file-size-preservation/)
- [Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway](https://scholariq.org/papers/multiple-myeloma-acquires-resistance-to-egfr-inhibitor-via-induction-of-pentose/)
- [Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy](https://scholariq.org/papers/histological-transformation-into-sclc-an-important-resistance-mechanism-of-nsclc/)
- [Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications](https://scholariq.org/papers/red-blood-cell-derived-materials-for-cancer-therapy-construction-distribution/)
- [LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma](https://scholariq.org/papers/lpcat1-promotes-gefitinib-resistance-via-upregulation-of-the-egfr-pi3k-akt/)
- [Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI](https://scholariq.org/papers/furmonertinib-for-egfr-mutant-advanced-non-small-cell-lung-cancer-a-glittering/)
- [Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study](https://scholariq.org/papers/etoposide-platinum-plus-anlotinib-for-patients-with-transformed-small-cell-lung-2/)
- [Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance](https://scholariq.org/papers/immunotherapy-based-therapy-as-a-promising-treatment-for-egfr-mutant-advanced/)
- [Effects of microRNA‑125b on multiple myeloma cell growth in vitro and in vivo](https://scholariq.org/papers/effects-of-microrna-125b-on-multiple-myeloma-cell-growth-in-vitro-and-in-vivo/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Jiujiang University](https://scholariq.org/institutions/jiujiang-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.